| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
260,040,000 |
| Market
Cap: |
115.77(B) |
| Last
Volume: |
1,382,430 |
Avg
Vol: |
1,612,685 |
| 52
Week Range: |
$323.57 - $446.08 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 400 MIDCAP |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 543 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
40,802 |
125,045 |
237,443 |
597,541 |
| Total Sell Value |
$17,242,133 |
$51,558,094 |
$92,174,963 |
$199,845,953 |
| Total People Sold |
7 |
11 |
14 |
18 |
| Total Sell Transactions |
18 |
36 |
60 |
125 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2022-02-01 |
4 |
D |
$243.64 |
$128,155 |
D/D |
(526) |
55,992 |
|
- |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
23,942 |
56,518 |
|
- |
|
| Mcglynn Margaret G |
Director |
– • – |
2022-01-28 |
4 |
AS |
$240.53 |
$1,208,960 |
D/D |
(5,000) |
1,099 |
|
13% |
|
| Mcglynn Margaret G |
Director |
– • – |
2022-01-28 |
4 |
OE |
$127.54 |
$637,700 |
D/D |
5,000 |
6,099 |
|
- |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2021-11-15 |
4 |
AS |
$186.80 |
$6,365 |
D/D |
(34) |
33,589 |
|
38% |
|
| Arbuckle Stuart A |
EVP, COO |
• – – |
2021-11-15 |
4 |
AS |
$186.99 |
$562 |
D/D |
(3) |
41,103 |
|
38% |
|
| Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2021-11-15 |
4 |
AS |
$186.78 |
$9,547 |
D/D |
(51) |
31,928 |
|
38% |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2021-11-01 |
4 |
D |
$185.07 |
$141,764 |
D/D |
(766) |
32,576 |
|
- |
|
| Kewalramani Reshma |
CEO & President |
• • – |
2021-08-19 |
4 |
B |
$195.14 |
$1,956,492 |
D/D |
10,000 |
73,754 |
2.81 |
14% |
|
| Sachs Bruce I |
Director |
– • – |
2021-08-02 |
4 |
B |
$197.91 |
$2,968,650 |
D/D |
15,000 |
41,210 |
2.39 |
5% |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2021-07-30 |
4 |
D |
$200.39 |
$153,499 |
D/D |
(766) |
33,342 |
|
- |
|
| Bhatia Sangeeta N. |
Director |
– • – |
2021-06-02 |
4 |
AS |
$208.96 |
$117,216 |
D/D |
(559) |
5,191 |
|
-15% |
|
| Mcglynn Margaret G |
Director |
– • – |
2021-06-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(699) |
1,099 |
|
- |
|
| Bozic Carmen |
EVP and CMO |
• – – |
2021-05-28 |
4 |
D |
$210.04 |
$65,322 |
D/D |
(311) |
32,953 |
|
- |
|
| Liu Joy |
SVP, General Counsel |
• – – |
2021-05-17 |
4 |
AS |
$215.95 |
$24,230 |
D/D |
(112) |
8,253 |
|
-15% |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2021-05-17 |
4 |
AS |
$215.95 |
$24,230 |
D/D |
(112) |
34,108 |
|
-15% |
|
| Arbuckle Stuart A |
EVP, Chief Comm & Ops Officer |
• – – |
2021-05-17 |
4 |
AS |
$215.33 |
$23,589 |
D/D |
(109) |
41,103 |
|
-15% |
|
| Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2021-05-17 |
4 |
AS |
$215.59 |
$9,736 |
D/D |
(45) |
40,133 |
|
-15% |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2021-05-17 |
4 |
AS |
$215.31 |
$17,093 |
D/D |
(79) |
33,589 |
|
-15% |
|
| Sanna Bastiano |
EVP, Cell & Genetic Therapies |
• – – |
2021-05-03 |
4 |
AS |
$218.06 |
$209,691 |
D/D |
(960) |
34,108 |
|
-13% |
|
| Mckenzie Diana |
Director |
– • – |
2021-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,842 |
3,277 |
|
- |
|
| Carney Lloyd |
Director |
– • – |
2021-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,842 |
5,401 |
|
- |
|
| Mcglynn Margaret G |
Director |
– • – |
2021-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
921 |
1,798 |
|
- |
|
| Bhatia Sangeeta N. |
Director |
– • – |
2021-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,842 |
5,750 |
|
- |
|
| Ambrose Kristen |
SVP & Chief Accounting Officer |
• – – |
2021-05-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,394 |
|
-13% |
|
1777 Records found
|
|
Page 16 of 72 |
|
|
4.57 (1.04%) 
